Up-regulation of C1GALT1 promotes breast cancer cell growth through MUC1-C signaling pathway

Oncotarget

Volumn 6, Issue 8, 2015, Pages 6123-6135

  Chou, Chih Hsing ^a   Huang, Miao Juei ^a   Chen, Chi Hau ^b   Shyu, Ming Kwang ^b   Huang, John ^b   Hung, Ji Shiang ^b   Huang, Chiun Sheng ^b   Huang, Min Chuan ^a,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Beta catenin; Breast cancer; C1GALT1; MUC1; T antigen

Indexed keywords

BETA CATENIN; CORE 1 BETA1,3 GALACTOSYLTRANSFERASE; GALACTOSYLTRANSFERASE; GLYCOPROTEIN; MESSENGER RNA; MUCIN 1C; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; C1GALT1 PROTEIN, HUMAN; MUC1 PROTEIN, HUMAN; MUCIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOMA; C1GALT1 GENE; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CELL MIGRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE SILENCING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR PROMOTION; UPREGULATION; ANIMAL; BREAST TUMOR; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BETA CATENIN; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GALACTOSYLTRANSFERASES; HETEROGRAFTS; HUMANS; MICE; MICE, SCID; MUCIN-1; SIGNAL TRANSDUCTION; TRANSFECTION; UP-REGULATION;

EID: 84925662960     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3045     Document Type: Article

References (46)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: a cancer journal for clinicians. 2005; 55:74-108.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64:9-29.
3. Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell. 2006; 126:855-867.
4. Moremen KW, Tiemeyer M, Nairn AV. Vertebrate protein glycosylation: diversity, synthesis and function. Nat Rev Mol Cell Biol. 2012; 13:448-462.
5. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99:10231-10233.
6. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO reports. 2006; 7:599-604.
7. Park JH, Nishidate T, Kijima K, Ohashi T, Takegawa K, Fujikane T, Hirata K, Nakamura Y, Katagiri T. Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis. Cancer research. 2010; 70:2759-2769.
8. Park JH, Katagiri T, Chung S, Kijima K, Nakamura Y. Polypeptide N-acetylgalactosaminyltransferase 6 disrupts mammary acinar morphogenesis through O-glycosylation of fibronectin. Neoplasia. 2011; 13:320-326.
9. Gill DJ, Tham KM, Chia J, Wang SC, Steentoft C, Clausen H, Bard-Chapeau EA, Bard FA. Initiation of GalNAc-type O-glycosylation in the endoplasmic reticulum promotes cancer cell invasiveness. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:E3152-3161.
10. Picco G, Julien S, Brockhausen I, Beatson R, Antonopoulos A, Haslam S, Mandel U, Dell A, Pinder S, Taylor-Papadimitriou J, Burchell J. Over-expression of ST3Gal-I promotes mammary tumorigenesis. Glycobiology. 2010; 20:1241-1250.
11. Sewell R, Backstrom M, Dalziel M, Gschmeissner S, Karlsson H, Noll T, Gatgens J, Clausen H, Hansson GC, Burchell J, Taylor-Papadimitriou J. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. The Journal of biological chemistry. 2006; 281:3586-3594.
12. Fu J, Wei B, Wen T, Johansson ME, Liu X, Bradford E, Thomsson KA, McGee S, Mansour L, Tong M, McDaniel JM, Sferra TJ, Turner JR, Chen H, Hansson GC, Braun J, et al. Loss of intestinal core 1-derived O-glycans causes spontaneous colitis in mice. The Journal of clinical investigation. 2011; 121:1657-1666.
13. Kudo T, Sato T, Hagiwara K, Kozuma Y, Yamaguchi T, Ikehara Y, Hamada M, Matsumoto K, Ema M, Murata S, Ohkohchi N, Narimatsu H, Takahashi S. C1galt1-deficient mice exhibit thrombocytopenia due to abnormal terminal differentiation of megakaryocytes. Blood. 2013; 122:1649-1657.
14. Alexander WS, Viney EM, Zhang JG, Metcalf D, Kauppi M, Hyland CD, Carpinelli MR, Stevenson W, Croker BA, Hilton AA, Ellis S, Selan C, Nandurkar HH, Goodnow CC, Kile BT, Nicola NA, et al. Thrombocytopenia and kidney disease in mice with a mutation in the C1galt1 gene. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103:16442-16447.
15. Wu YM, Liu CH, Huang MJ, Lai HS, Lee PH, Hu RH, Huang MC. C1GALT1 enhances proliferation of hepatocel-lular carcinoma cells via modulating MET glycosylation and dimerization. Cancer research. 2013; 73:5580-5590.
16. Hung JS, Huang J, Lin YC, Huang MJ, Lee PH, Lai HS, Liang JT, Huang MC. C1GALT1 overexpression promotes the invasive behavior of colon cancer cells through modifying O-glycosylation of FGFR2. Oncotarget. 2014; 5:2096-2106.
17. Cazet A, Julien S, Bobowski M, Burchell J, Delannoy P. Tumour-associated carbohydrate antigens in breast cancer. Breast cancer research: BCR. 2010; 12:204.
18. Patil SA, Bshara W, Morrison C, Chandrasekaran EV, Matta KL, Neelamegham S. Overexpression of alpha2, 3sialyl T-antigen in breast cancer determined by miniaturized glycosyltransferase assays and confirmed using tissue microarray immunohistochemical analysis. Glycoconjugate journal. 2014; 31:509-521.
19. Schindlbeck C, Jeschke U, Schulze S, Karsten U, Janni W, Rack B, Sommer H, Friese K. Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen-Friedenreich tumor antigen. Histochemistry and cell biology. 2005; 123:631-637.
20. Whitehouse C, Burchell J, Gschmeissner S, Brockhausen I, Lloyd KO, Taylor-Papadimitriou J. A transfected sialyltransferase that is elevated in breast cancer and localizes to the medial/trans-Golgi apparatus inhibits the development of core-2-based O-glycans. The Journal of cell biology. 1997; 137:1229-1241.
21. Brockhausen I, Yang JM, Burchell J, Whitehouse C, Taylor-Papadimitriou J. Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. European journal of biochemistry/FEBS. 1995; 233:607-617.
22. Mungul A, Cooper L, Brockhausen I, Ryder K, Mandel U, Clausen H, Rughetti A, Miles DW, Taylor-Papadimitriou J, Burchell JM. Sialylated core 1 based O-linked glycans enhance the growth rate of mammary carcinoma cells in MUC1 transgenic mice. International journal of oncology. 2004; 25:937-943.
23. Yu LG, Andrews N, Zhao Q, McKean D, Williams JF, Connor LJ, Gerasimenko OV, Hilkens J, Hirabayashi J, Kasai K, Rhodes JM. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. The Journal of biological chemistry. 2007; 282:773-781.
24. Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends in molecular medicine. 2014; 20:332-342.
25. Kaur S, Kumar S, Momi N, Sasson AR, Batra SK. Mucins in pancreatic cancer and its microenvironment. Nature reviews Gastroenterology & hepatology. 2013; 10:607-620.
26. Razawi H, Kinlough CL, Staubach S, Poland PA, Rbaibi Y, Weisz OA, Hughey RP, Hanisch FG. Evidence for core 2 to core 1 O-glycan remodeling during the recycling of MUC1. Glycobiology. 2013; 23:935-945.
27. Madsen CB, Lavrsen K, Steentoft C, Vester-Christensen MB, Clausen H, Wandall HH, Pedersen AE. Glycan elongation beyond the mucin associated Tn antigen protects tumor cells from immune-mediated killing. PloS one. 2013; 8:e72413.
28. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nature reviews Cancer. 2009; 9:874-885.
29. Kufe DW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 2013; 32:1073-1081.
30. Alam M, Ahmad R, Rajabi H, Kharbanda A, Kufe D. MUC1-C oncoprotein activates ERK->C/EBPbeta signaling and induction of aldehyde dehydrogenase 1A1 in breast cancer cells. The Journal of biological chemistry. 2013; 288:30892-30903.
31. Marth JD, Grewal PK. Mammalian glycosylation in immunity. Nature reviews Immunology. 2008; 8:874-887.
32. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nature reviews Cancer. 2004; 4:45-60.
33. Mukhopadhyay P, Chakraborty S, Ponnusamy MP, Lakshmanan I, Jain M, Batra SK. Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochimica et biophysica acta. 2011; 1815:224-240.
34. Wang ZQ, Bachvarova M, Morin C, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Bachvarov D. Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation. Oncotarget. 2014; 5:544-560.
35. Julien S, Ivetic A, Grigoriadis A, QiZe D, Burford B, Sproviero D, Picco G, Gillett C, Papp SL, Schaffer L, Tutt A, Taylor-Papadimitriou J, Pinder SE, Burchell JM. Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers. Cancer research. 2011; 71:7683-7693.
36. Lillehoj EP, Han F, Kim KC. Mutagenesis of a Gly-Ser cleavage site in MUC1 inhibits ectodomain shedding. Biochemical and biophysical research communications. 2003; 307:743-749.
37. Julian J, Dharmaraj N, Carson DD. MUC1 is a substrate for gamma-secretase. Journal of cellular biochemistry. 2009; 108:802-815.
38. Zhang L, Gallup M, Zlock L, Chen YT, Finkbeiner WE, McNamara NA. Pivotal role of MUC1 glycosylation by cigarette smoke in modulating disruption of airway adherens junctions in vitro. The Journal of pathology. 2014; 234:60-73.
39. Boskovski MT, Yuan S, Pedersen NB, Goth CK, Makova S, Clausen H, Brueckner M, Khokha MK. The heterotaxy gene GALNT11 glycosylates Notch to orchestrate cilia type and laterality. Nature. 2013; 504:456-459.
40. Kufe DW. Functional targeting of the MUC1 oncogene in human cancers. Cancer biology & therapy. 2009; 8:1197-1203.
41. Raina D, Ahmad R, Joshi MD, Yin L, Wu Z, Kawano T, Vasir B, Avigan D, Kharbanda S, Kufe D. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer research. 2009; 69:5133-5141.
42. Blixt O, Bueti D, Burford B, Allen D, Julien S, Hollingsworth M, Gammerman A, Fentiman I, Taylor-Papadimitriou J, Burchell JM. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast cancer research: BCR. 2011; 13:R25.
43. Burford B, Gentry-Maharaj A, Graham R, Allen D, Pedersen JW, Nudelman AS, Blixt O, Fourkala EO, Bueti D, Dawnay A, Ford J, Desai R, David L, Trinder P, Acres B, Schwientek T, et al. Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer. British journal of cancer. 2013; 108:2045-2055.
44. Astronomo RD, Burton DR. Carbohydrate vaccines: developing sweet solutions to sticky situations? Nature reviews Drug discovery. 2010; 9:308-324.
45. Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, Pathangey LB, Madsen CS, Cohen PA, Gendler SJ, Boons GJ. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:261-266.
46. Ramsby M, Makowski G. Differential detergent fractionation of eukaryotic cells. Cold Spring Harbor protocols. 2011; 2011:prot5592.